CDNA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CareDx is not a clear buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has improved technical structure and several positive business catalysts, but the current setup is already near resistance, options sentiment is very bullish but also crowded, and there is no strong proprietary buy signal today. For an impatient investor, this is more of a hold than an immediate buy.
CDNA is in an uptrend technically: SMA_5 > SMA_20 > SMA_200, and MACD histogram is positive at 0.387, though it is contracting, which suggests momentum is still positive but not accelerating. RSI_6 at 74.186 indicates the stock is stretched and nearing overbought conditions rather than offering a clean entry. Price at 29.19 is just below R1 resistance at 29.508 and below R2 at 30.94, while the pivot is 27.189, so upside exists but the near-term reward-to-risk is less attractive at current levels. The stock trend model also suggests short-term weakness is possible.
Recent catalysts are positive. CareDx completed the acquisition of Naveris for $160 million with an additional $100 million tied to revenue milestones, which strengthens its cancer monitoring business and could support higher growth and margins. The company also finalized the sale of its Lab Products division to Eurobio Scientific for €145 million, which helps streamline the portfolio and move toward a more focused, potentially higher-quality business mix. Analyst commentary is constructive, with BTIG pointing to possible revenue upside versus the company’s 2027 target.
There is no strong proprietary buy signal today: AI Stock Picker shows no signal and SwingMax also shows no recent signal. The stock is near resistance, RSI is elevated, and similar candlestick pattern analysis suggests a 60% chance of a -2.05% move next day, which weakens the case for an immediate entry. Hedge fund and insider trading trends are neutral, so there is no strong institutional or insider confirmation. Congress trading data is unavailable, so there is no political buying support to factor in.
No quarterly financial statement details were provided because the financial snapshot is unavailable. Based on the news and analyst commentary, the latest quarter appears to have included positive strategic updates and improving growth expectations, especially around the core transplant business and the new MRD opportunity from Naveris. The latest quarter season referenced in the analyst update is Q1.
BTIG raised its price target to $28 from $26 and maintained a Buy rating, citing positive Q1 updates, the Naveris acquisition, and expectations that CareDx can outperform its 2027 revenue target of $500M. Overall analyst sentiment appears constructive, with a bullish long-term narrative centered on growth reacceleration and a better business mix. The main pro is the upgraded growth story; the main con is that the stock is already trading above the cited target, which limits immediate upside from this particular note.
